Jump Financial LLC Cuts Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jump Financial LLC trimmed its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 4.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,308 shares of the biotechnology company’s stock after selling 2,458 shares during the period. Jump Financial LLC’s holdings in Arcturus Therapeutics were worth $989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Arcturus Therapeutics by 6.8% during the fourth quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company’s stock valued at $28,587,000 after purchasing an additional 107,635 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Arcturus Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company’s stock valued at $9,421,000 after acquiring an additional 3,186 shares during the last quarter. Empire Life Investments Inc. grew its position in Arcturus Therapeutics by 85.5% in the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock worth $4,742,000 after acquiring an additional 128,771 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Arcturus Therapeutics by 5.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 207,802 shares of the biotechnology company’s stock worth $3,526,000 after acquiring an additional 10,180 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Arcturus Therapeutics by 54.6% in the 3rd quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock valued at $2,412,000 after purchasing an additional 36,714 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Stock Up 2.2 %

Shares of NASDAQ:ARCT opened at $10.53 on Monday. The business’s 50 day moving average is $13.26 and its 200 day moving average is $16.38. The stock has a market cap of $285.57 million, a P/E ratio of -4.74 and a beta of 3.41. Arcturus Therapeutics Holdings Inc. has a 52-week low of $8.04 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million for the quarter, compared to analysts’ expectations of $44.64 million. On average, sell-side analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ARCT. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Wells Fargo & Company reduced their price objective on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Canaccord Genuity Group cut their target price on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Finally, BTIG Research set a $48.00 price target on Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $59.20.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.